Compound · sermorelin
T1Peptide

Sermorelin

Synthetic analog of the first 29 amino acids of endogenous GHRH. Stimulates physiological pulsatile GH release from the anterior pituitary. FDA-approved for diagnosis and treatment of growth hormone deficiency in children. Preserves the hypothalamic-pituitary feedback loop.

Half-life
10-20 minutes
Bioavailability
Systemic via subcutaneous injection
Route
subcutaneous
Evidence tier
T1 — Multiple RCTs
Optimization pillars
anti-aging · recovery
References
2 peer-reviewed
Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative
100–200 mcg/day at bedtime
GH support
moderate
200–300 mcg/day at bedtime
Anti-aging protocol
aggressive
300–500 mcg/day at bedtime
Maximum GH optimization
Monitoring
  • igf-1
  • fasting-glucose
  • fasting-insulin
Contraindications
  • active-cancer
  • pituitary-tumor
References
  • PMID:9467534Sermorelin: a review of its pharmacology and clinical useClin Pharm, 1997
  • PMID:12172220Effects of sermorelin on sleep quality and nocturnal growth hormone secretionNeuroendocrinology, 2002
Notes

Sermorelin is the original GH peptide. FDA-approved. Well-characterized pharmacology. The reason newer peptides like Mod GRF 1-29 exist is that sermorelin degrades quickly — the amino acid substitutions in Mod GRF extend stability. But sermorelin has something the newer analogs do not. Regulatory approval and decades of safety data. For the risk-conscious user, the proven track record has value that novelty does not.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Sermorelin in a protocol matched to you

OPTIMIZE · a protocols.is product